HIGHLIGHTS
- who: Juan A. Marí et al. from the Kobe University, Japan have published the research work: Paclitaxel Plus Cetuximab as Induction Chemotherapy for Patients With Locoregionally Advanced Head and Neck Squamous Cell Carcinoma Unfit for Cisplatin-Based Chemotherapy, in the Journal: (JOURNAL)
SUMMARY
In these last two settings, the use of induction chemotherapy (ICT) has been widely debated but it remains a valid option to select patients for larynx-preservation strategy or for those patients with rapidly growing and/or high tumor burden. A significant proportion of patients with newly diagnosed LA . . .
If you want to have access to all the content you need to log in!
Thanks :)
If you don't have an account, you can create one here.